Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)

Grant

Date/time Interval

  • August 15, 2015 - April 30, 2016
  • Total Award Amount

  • 357577.00
  • Direct Costs

  • 243249.00
  • Sponsor Award Id

  • 2011A051506/223110
  • Contributor

  • Birur, Badari   Investigator  
  • Jindal, Ripu   Investigator  
  • May, Roberta   Investigator  
  • Shelton, Richard   Principal Investigator